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Abstract
Background: Calcium supplements are widely used among older adults for osteoporosis prevention and treatment.
However, their effect on creatinine levels and kidney function has not been well studied.
Methods: We investigated the effect of calcium supplementation on blood creatinine concentration in a randomized
controlled trial of colorectal adenoma chemoprevention conducted between 2004–2013 at 11 clinical centers in the United
States. Healthy participants (N = 1,675) aged 45–75 with a history of colorectal adenoma were assigned to daily
supplementation with calcium (1200 mg, as carbonate), vitamin D3 (1000 IU), both, or placebo for three or five years.
Changes in blood creatinine and total calcium concentration were measured after one year of treatment and multiple linear
regression was used to estimate effects on creatinine concentrations.
Results: After one year of treatment, blood creatinine was 0.01360.006 mg/dL higher on average among participants
randomized to calcium compared to placebo after adjustment for other determinants of creatinine (P = 0.03). However, the
effect of calcium treatment appeared to be larger among participants who consumed the most alcohol (2–6 drinks/day) or
whose estimated glomerular filtration rate (eGFR) was less than 60 ml/min/1.73 m2 at baseline. The effect of calcium
treatment on creatinine was only partially mediated by a concomitant increase in blood total calcium concentration and
was independent of randomized vitamin D treatment. There did not appear to be further increases in creatinine after the
first year of calcium treatment.
Conclusions: Among healthy adults participating in a randomized clinical trial, daily supplementation with 1200 mg of
elemental calcium caused a small increase in blood creatinine. If confirmed, this finding may have implications for clinical
and public health recommendations for calcium supplementation.
Trial Registration: ClinicalTrials.gov NCT00153816
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clinical trial investigating the efficacy of vitamin D, calcium, or
both for preventing sporadic colorectal adenoma recurrence.
Participants were independently randomized to calcium or
vitamin D in a modified two-by-two factorial design. In the ‘‘Full
Factorial’’ component of the study, participants were randomized
with equal probability to four treatment arms: 1000 IU/day
vitamin D3, 1200 mg/day elemental calcium (as carbonate), both
vitamin D3 and calcium, or placebo. In this report, which analyzes
the effect of calcium treatment, we compare the two groups
randomized to calcium (calcium alone or calcium+vitamin D) to
the two ‘‘control’’ groups randomized to no calcium (placebo or
vitamin D alone). In the ‘‘Two Arm’’ component of the study,
women who chose to receive calcium supplementation were
randomized with equal probability to either vitamin D3 plus
calcium or to calcium alone, and are excluded from this report
since they were not randomized to calcium treatment. The
expected duration of the intervention was either 3 or 5 years,
according to the colonoscopy follow-up interval recommended by
the participants’ physicians. Sample size was determined by the
hypothesized treatment effect on the primary outcome of adenoma
recurrence.
Participants were recruited from gastroenterology departments
and practices associated with eleven clinical centers in the United
States; the Project Coordination Center and trial database are
located at The Geisel School of Medicine at Dartmouth.

Introduction
Calcium supplements are widely recommended and commonly
used in the United States, especially by postmenopausal women
for preventing and treating osteoporosis [1–4]. Extraskeletal health
benefits of calcium have also been proposed, including a reduction
in risk of colorectal neoplasms [5–8]. Although observational
studies originally suggested inverse associations with cardiovascular disease, recent analyses of clinical trials [9–11] as well as a large
prospective cohort study [12] suggest increased cardiovascular risk
from calcium supplementation. However, another recent analysis
did not find increased cardiovascular risk [13]. Additionally, two
recent studies provide evidence of a reduction in all cause
mortality from calcium supplementation alone [14] or with
vitamin D [15]. Potential adverse renal effects of calcium
supplementation include an increased risk of kidney stones [16]
and renal insufficiency associated with hypercalcemia and
metabolic alkalosis in the calcium-alkali syndrome [17]. Further
research is needed to investigate the extraskeletal effects of
supplemental calcium use.
In a randomized controlled trial of the effects of calcium and/or
vitamin D supplementation on colorectal adenoma recurrence,
changes in blood creatinine concentration were measured as a prespecified interim outcome for safety to assess potential renal
effects. We observed that calcium treatment for one year was
associated with a small increase in blood creatinine concentration,
suggesting the possibility of an effect on renal function. In the
current report, we analyze the association of calcium treatment
with changes in blood creatinine among the predominantly male,
45–75 year old participants in the full factorial component of our
trial.

Eligibility, Enrollment and Randomization
Eligible patients were 45–75 years of age, in good general
health, and had at least one large bowel adenoma removed at a
colonoscopy within four months before enrollment with a
recommended follow-up interval of either 3 or 5 years. Other
inclusion criteria included blood total calcium within the normal
range, creatinine #20% above the upper limit of normal, and 25hydroxyvitamin D between 12–90 ng/ml. Exclusion criteria
included a history of a familial colorectal cancer syndromes,
invasive large bowel cancer, malabsorption syndromes, and
indications or contraindications to the study agents (e.g., kidney
stones, granulomatous diseases, hyperparathyroidism, hypercalcemia, osteoporosis, osteomalacia, or use of interacting drugs).
Participant recruitment began on 5/15/04 and enrollment
occurred between July 16, 2004 and July 31, 2008. At enrollment,
a detailed questionnaire was administered to collect demographic,
medical and lifestyle data. Race and Hispanic ethnicity were selfreported. Current height and weight were documented, blood was
collected, and participants completed a Block Brief 2000 Food
Frequency Questionnaire (NutritionQuest, Berkeley, CA). Participants were counseled to avoid additional supplementation with
calcium or vitamin D during the study and to reduce their dietary
consumption of calcium if it exceeded 1200 mg/day. Study
multivitamins, formulated without any calcium or vitamin D, were
provided to participants if desired. At enrollment, participants
began a blinded placebo run-in period (56–84 days) to assess
adherence to study procedures before randomization; participants
who took ,80% of their study pills were not randomized. A webbased program was used to randomize participants in blocks with
computer-generated random numbers; stratification factors included full factorial participation, clinical center, sex, and
colonoscopic follow-up interval (3 or 5 years). Identical appearing
study pills contained calcium (600 mg elemental calcium as
carbonate), vitamin D3 (500 IU), both agents, or placebo with
instructions to take one tablet twice daily with food. Participants,
health care providers and investigators were blinded to treatment
assignments.

Methods
Ethics Statement
This study was registered at ClinicalTrials.gov as
NCT00153816 (www.clinicaltrials.gov) on September 7, 2005,
when the investigators first became aware of the opportunity for
trial registration. The authors confirm that all ongoing and related
trials for this drug/intervention are registered. The following
institutional review boards (IRBs) approved the study prior to its
initiation at that site (date of initial approvals are in parentheses):
Dartmouth College Committee for the Protection of Human
Subjects (8/25/03), University of Southern California IRB (3/17/
04), Kaiser Permanente IRB (5/27/04), Colorado Multiple
Institutional Review Board (7/23/04), Emory University IRB
(4/12/04), Atlanta Veterans Affairs Medical Center (VAMC) IRB
(4/12/04), University of Iowa IRB (6/9/04), University of
Minnesota IRB (6/3/04), Minneapolis VAMC IRB (6/29/04),
Portsmouth Regional Hospital IRB (3/24/04), Concord Hospital
IRB (4/1/04), Maine Medical Center IRB (6/7/04), White River
Junction VAMC IRB (3/4/04), University of North Carolina IRB
(5/24/04), Cleveland Clinic IRB (5/21/04), University of Puerto
Rico IRB (9/25/06), San Juan VAMC IRB (11/7/06), Palmetto
Health IRB (4/13/04), University of Texas/MD Anderson
Cancer Center IRB (4/7/04). All participants provided written
informed consent at enrollment. An independent Safety and Data
Monitoring Committee reviewed the study semiannually.

Study Design
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1. The Vitamin D/Calcium Polyp Prevention Study
was a multicenter, placebo-controlled, double-blind, randomized
PLOS ONE | www.plosone.org
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forced into the model and other participant characteristics were
chosen for inclusion by backward elimination using the Akaike
Information criterion. Sensitively analyses were conducted to test
the robustness of the results among non-Hispanic whites only,
optimally compliant participants, or participants with a year one
creatinine measurement performed in the same laboratory as their
baseline measurement. In exploratory analyses, effect modification
was examined using Wald tests for interactions between calcium
treatment and other covariates. Due to the large number of
participants missing data on baseline dietary calcium intake (8%),
this variable was excluded from sub-group analyses on the small
number of participants with baseline eGFR,60 ml/min/1.73 m2.
Analyses were conducted according to the intent-to-treat principle,
except as indicated. All statistical tests were two-sided and
considered significant at a value of P,0.05. Statistical analyses
were performed using SAS (version 9.3, Cary, NC).

Follow-up
Participants were interviewed every six months by telephone
regarding adherence to study treatment; use of medications and
nutritional supplements; symptoms, illnesses, medical procedures
and hospitalizations; and dietary intake of calcium and vitamin D.
As pre-specified in the protocol, interim visits were scheduled to
measure blood total calcium, creatinine, and 25-hydroxyvitamin D
one year after randomization, and three years after randomization
for participants with a 5-year follow-up. Participants were
removed from treatment if their calcium was above the normal
range, if their creatinine was .20% above the upper limit of
normal, or if their 25-hydroxyvitamin D was ,10 or.100 ng/ml.
In addition, 25-hydroxyvitamin D was measured at ‘‘end-oftreatment visits’’ scheduled shortly before the participants’ followup colonoscopies. Creatinine was measured at this time as well for
participants who elected to take part in a ‘‘kidney sub-study’’ of the
renal effects of vitamin D, which was active between September
2010 and April 2012. Additionally, in October 2011 the Safety
and Data Monitoring Committee unblinded the study investigators to the observed association of calcium treatment with elevated
blood creatinine levels. As a result, the protocol was modified to
include creatinine and calcium measurements annually, to remove
participants from randomized calcium treatment if their creatinine
was above the upper limit of normal or if there was an increase of
$0.3 mg/dL from baseline, and to retrospectively measure
creatinine and calcium on stored specimens from ‘‘end-oftreatment visits’’ that were completed previously without creatinine measurements (at Quest Diagnostics, Denver, CO). Fasting
prior to study blood draws was recommended but not required.
Participant follow-up in the treatment phase of the study ended on
August 31, 2013 and the main results are currently being analyzed.

Results
A total of 1,675 participants were randomized in the Full
Factorial component of the study (Figure 1). Baseline demographic, lifestyle and other relevant characteristics were similar between
participants in the control or calcium treatment groups (Table 1).
The mean age at enrollment was approximately 58 years, 85% of
participants were male and 85% were Caucasian. Baseline blood
creatinine, total calcium, and 25-hydroxyvitamin D concentrations
were also similar among participants in the control or calcium
treatment groups. A total of 28 participants (1.7%) had an elevated
creatinine within 20% above the lab normal range and 66 (3.9%)
had an eGFR less than 60 ml/min/1.73 m2, a level that, if
persistent, commonly defines chronic kidney disease [18].
Numbers of and reasons for unobtainable blood draws at years
one, three and five were similar between the treatment arms
(Figure 1). Overall, 97.1% of participants (N = 1,627) had a year
one blood draw (Figure 1), which was collected 14.761.4 months
(mean 6 SD) from the baseline blood draw. In the period between
the baseline and year one blood draw, 81.6% of participants
(N = 1,367) were ‘‘optimally compliant’’, defined as taking at least
80% of their study pills, having no gaps in pill taking greater than
7 consecutive days, and taking no personal calcium supplements.
At year one, randomized calcium treatment was associated with
a slightly larger increase in blood creatinine concentration:
0.03860.004 versus 0.02160.004 mg/dL (mean 6 SE)
(P = 0.01) (Table 2). Among participants with a normal creatinine
at baseline, more in the calcium treatment group developed
creatinine concentrations above the normal laboratory reference
range at year one (27 participants in the calcium group and 13 in
the control group, P = 0.02). In addition, more subjects in the
calcium treatment group experienced creatinine increases of at
least 0.3 mg/dL at year one (41 in the calcium group and 26 in the
control group, P = 0.06). As expected, calcium treatment was also
associated with modestly increased blood total calcium concentration (Table 2). In exploratory analyses, in the intervals between
years one and three and between years three and five, there did
not appear to be further increases in blood creatinine or calcium
concentrations due to calcium treatment in analyses including all
participants (Table 2) or in analyses restricted to participants with
blood measurements performed in the same lab as at the prior
time point (Table S1).
Next, we examined the effect of calcium supplementation on year
one creatinine concentration adjusted for baseline creatinine and
other potential determinants of renal function (Table 3). Overall,
the regression model explained 60% of the variance in year one
creatinine (r2 = 0.596). After controlling for characteristics listed in

Laboratory Measurements
Measurements of creatinine and calcium were performed on
fresh serum or plasma samples according to standard procedures
at laboratories associated with the eleven participating clinical
centers. Local laboratory reference ranges were used to identify
out-of-range values. Three clinical centers changed laboratories
during the study. Additionally, measurements of creatinine and
calcium on frozen serum samples collected at ‘‘end-of-treatment
visits’’ completed prior to October 2011 were performed at Quest
Diagnostics (Denver, CO): creatinine was measured using a kinetic
modified Jaffe method (Beckman Coulter Inc., Brea, CA) and total
calcium was measured using an Arsenazo assay (Beckman Coulter
Inc.). All 25-hydroxyvitamin D measurements were performed on
frozen serum samples at the University of California (Los Angeles)
at the Nutrition Research Center Laboratory using a radioimmunoassay kit from Immunodiagnostic Systems (IDS, Fountain Hills,
AZ).

Statistical Analyses
Study sample size was based on power calculations for the
primary outcome of adenoma recurrence. T-tests were used to
compare blood creatinine and total calcium concentrations
between treatment groups. A chi-square test was used to compare
the number of participants by treatment group with elevated (outof-range) creatinine concentrations or with increases of $0.3 mg/
dL between baseline and year one. Estimated glomerular filtration
rate (eGFR) was calculated using the CKD-EPI equation [18].
Multiple linear regression was used to estimate the effect of
calcium treatment on untransformed year one creatinine concentration or eGFR, adjusting for the baseline level of the respective
outcomes. To generate parsimonious models, race, Hispanic
ethnicity and randomized vitamin D treatment assignment were
PLOS ONE | www.plosone.org
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Figure 1. Vitamin D/Calcium Polyp Prevention Study Participant Flow Diagram.
doi:10.1371/journal.pone.0108094.g001

Notably, randomized vitamin D treatment did not effect year
one creatinine concentration (Table 3) or modify the effect of
calcium treatment on year one creatinine concentration (Pinteraction = 0.54). It also did not statistically significantly effect blood
calcium concentration at year one, although it was associated with
a net increase in 25-hydroxyvitamin D concentration of 6.7 ng/ml
(P,0.001).
In exploratory analyses, there was suggestive evidence from
subgroup analyses that two factors modified the effect of calcium
supplementation. First, the effect of calcium appeared to be more
pronounced among participants (N = 62) with baseline eGFR ,
60 ml/min/1.73 m2: at year one creatinine was on average
0.1060.05 mg/dL higher (mean 6 SE) (P = 0.06, Pinteraction = 0.01) and the adjusted year one eGFR was on average
4.962.7 ml/min/1.73 m2 lower (mean 6 SE) (P = 0.07, Pinteraction = 0.10). Due to the high rate of missing data on baseline dietary
calcium intake, it was excluded from this sub-group analysis;
however, its inclusion did not change the results. Second, greater

Table 3, year one creatinine values were on average
0.01360.006 mg/dL (mean 6 SE) higher in the calcium treatment
group than the control group (P = 0.03). In sensitivity analyses,
almost identical results were seen when the analysis was restricted to
optimally compliant participants (0.01360.007 mg/dL, P = 0.05),
to non-Hispanic whites only (0.01360.007 mg/dL, P = 0.06), or to
participants with year one creatinine measurements performed in
the same laboratory as their baseline measurement
(0.01560.006 mg/dL, P = 0.02).
To determine whether the concomitant increase in blood
calcium mediated the effect of calcium supplementation on
creatinine concentration (an increase of 0.01360.006 mg/dL,
mean 6 SE), year one blood calcium concentration was added to
the regression model. For every 1 mg/dL increase in year one
calcium concentration there was an increase of 0.03960.008 mg/
dL (mean 6 SE) in year one creatinine (P,0.0001) and the
coefficient for calcium treatment decreased by about 23% to
0.01060.006 mg/dL (mean 6 SE) (P = 0.11).
PLOS ONE | www.plosone.org
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Table 1. Baseline Characteristics of Participants in the Full Factorial Component of the Vitamin D/Calcium Polyp Prevention Study,
by Calcium Treatment Group (N = 1,675).

Characteristic

Control1 (N = 835)

Calcium2 (N = 840)

Sex (male)

713 (85.4)

710 (84.5)

Age (years)

58.367.0

58.766.9

Race:
Caucasian

721 (86.4)

704 (83.8)

African American

52 (6.2)

79 (9.4)

Asian/Pacific Islander

22 (2.6)

16 (1.9)

Other/Unknown

40 (4.8)

41 (4.9)

Hispanic Ethnicity

43 (5.2)

49 (5.9)

Body Mass Index [weight (kg)/height(m2)]

29.1 (4.7)

29.2 (5.1)

None

258 (31.1)

255 (30.6)

0.1–1.9

441 (53.1)

462 (55.4)

2–6

131 (15.8)

117 (14.0)

Never

404 (48.4)

416 (49.5)

Former

357 (42.8)

343 (40.8)

Current

74 (8.9)

81 (9.6)

Physical Activity: Total MET minutes per week

319763030

319662996

Taking multivitamin

432 (51.7)

442 (52.7)

Taking calcium supplement3

65 (7.8)

65 (7.8)

Dietary calcium intake (mg/day)

6586300

6856316

Dietary vitamin D intake (IU/day)

135699

138694

Blood creatinine (mg/dL)

0.9760.16

0.9760.17

Alcohol Intake (drinks/day):

Smoking status:

Blood creatinine above lab normal range

13 (1.6)

15 (1.8)

eGFR4 ,60 ml/min/1.73 m2

30 (3.6)

36 (4.3)

Blood total calcium (mg/dL)

9.3560.38

9.3460.39

Serum 25-hydroxyvitamin D (ng/ml)

24.668.1

24.668.6

Diuretic use5

144 (17.3)

141 (16.8)

Aspirin use daily

308 (36.9)

300 (35.7)

Non-aspirin NSAID use daily

60 (7.2)

59 (7.0)

Diabetes6

66 (7.9)

85 (10.1)

Data are means 6 SD or number of participants (% of total).
1
Includes placebo and vitamin D treatment arms.
2
Includes calcium and calcium plus vitamin D treatment arms.
3
Taking a calcium supplement separate from a multivitamin.
4
Estimated glomerular filtration rate (eGFR) calculated using the CKD-EPI equation [18].
5
Includes use of loop, thiazide, and K+-sparing diuretics.
6
Participant self-report of diabetes diagnosis or use of medication(s) for diabetes.
Number of participants with missing data: Hispanic ethnicity 3 (1 placebo, 2 calcium); BMI 1 (placebo); alcohol 11 (5 placebo, 6 calcium); taking multivitamin 2 (calcium);
taking calcium supplement 3 (1 placebo, 2 calcium); dietary calcium and vitamin D 129 (64 placebo, 65 calcium); diabetes 1 (placebo).
doi:10.1371/journal.pone.0108094.t001

baseline alcohol consumption appeared to be associated with a
larger effect of calcium treatment, although the interaction was not
statistically significant. Among participants in the highest category
of baseline alcohol consumption (2 to 6 drinks per day, N = 239),
year one creatinine was on average 0.03460.016 mg/dL (mean 6
SE) higher among participants randomized to calcium treatment
(P = 0.04, Pinteratcion = 0.07 for alcohol consumption modeled as
continuous variable).

PLOS ONE | www.plosone.org

Discussion
Calcium supplementation (1200 mg/day of elemental calcium,
as calcium carbonate) led to a very modest increase in blood
creatinine concentration in a population of generally healthy 45–
75 year old adults, predominantly white (85%) and male (85%),
who were participating in a randomized clinical trial. After one
year, creatinine concentration was 0.013 mg/dL higher on
average among participants in the calcium treatment group
compared to the control group after adjusting for other
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0.44

,0.0001

0.09

0.74

0.68

0.01

P5

determinants of creatinine concentration. However, in exploratory
analyses, the effect of calcium supplementation appeared to be
more pronounced among participants with baseline eGFR ,
60 ml/min/1.73 m2 or among those consuming the most alcohol
(2–6 drinks/day). There was no evidence that randomized vitamin
D treatment independently affected creatinine or modified the
effect of calcium supplementation. In addition, in exploratory
analyses, the effect appeared to be sustained but not progressive
beyond the first year of calcium supplementation.
Although numerous studies have investigated randomized
calcium supplementation for osteoporosis prevention or treatment
[19–29], and/or cancer prevention [5,28,30–32], we could only
find two that reported the effect of calcium supplementation on
blood creatinine. In one [33], 438 participants aged 60 years or
older were randomized to placebo or 600 IU 25-hydroxyvitamin
D or 750 mg elemental calcium for 4 years. The change in serum
creatinine was not significantly different between the three
treatment groups. However, in a study of 295 women aged 46–
55 years randomized to either 1000 or 2000 mg of elemental
calcium daily or no supplementation for 2 years [34], there was a
small but statistically significant increase in serum creatinine in the
calcium supplementation groups, in agreement with our findings.
The mechanism by which calcium supplementation increases
blood creatinine is unknown, but could be due to an effect on renal
function. Some of the effect could be due to the very modest
increase in blood calcium due to calcium supplementation,
possibly through a hemodynamic mechanism. Our statistical
analyses suggest that the increase in blood calcium concentration
explained only about 23% of the increase in creatinine concentration due to calcium supplementation at year one. Other
potential mechanisms include mild vasoconstriction due to
increased calciuria or induction of natriuresis by calcium [35],
which could cause mild dehydration, or possibly increased
calcification of the glomeruli. Notably, it has been suggested that
glomerulosclerosis and atherosclerosis share common mechanisms
[36] and increased vascular calcification has been suggested as a
possible mechanism for an increase in cardiovascular events with
calcium supplementation [11]. Alternatively, calcium supplementation may increase the creatinine load or change renal handling
of creatinine without a direct effect on kidney function (i.e.,
without reducing glomerular filtration). For example, treatment
with an active vitamin D analogue increased creatinine production
and serum creatinine without modifying the glomerular filtration
rate [37]. Further research investigating other biomarkers of renal
function (e.g, cystatin C) could help to distinguish between these
possibilities.
The clinical relevance of the increase in creatinine associated
with one year of calcium supplementation in our study is
uncertain, but our exploratory analyses suggest that it may be
larger and therefore more important in individuals with preexisting renal impairment or alcohol consumption. Notably, rapid
declines in kidney function of the magnitude reported here for the
participants with pre-existing renal impairment (5 ml/min/
1.73 m2) have been associated with increased cardiovascular risk
and mortality [38,39]. In addition, even among participants with
normal creatinine concentration at baseline in our study,
significantly more developed creatinine concentrations above the
normal reference range in the calcium group compared to the
control group. However, some common medications that increase
creatinine are nonetheless associated with renal protection [40]. In
general, more attention to potential adverse effects of dietary
supplements is warranted [41,42]. Although some evidence
supports the use of calcium supplements for the prevention and
treatment of osteoporosis [43,44], the evidence for calcium alone

20.03660.028

2

1

20.06760.031
9.2160.47
289
Year 5, and change from year 3

20.04760.014

726

20.06260.016

9.3060.37

9.2460.40

Year 1, and change from baseline 814

Total Calcium

Year 3, and change from year 1

20.04260.008

20.04260.007

345
Year 5, and change from year 3

0.9560.19

0.9660.23
749
Year 3, and change from year 1

PLOS ONE | www.plosone.org

Includes placebo and vitamin D treatment arms.
Includes calcium and calcium plus vitamin D treatment arms.
3
Data are means 6 SD.
4
Data are means 6 SE.
5
T-test for comparison of change in creatinine or total calcium concentrations in control vs. calcium treatment groups.
doi:10.1371/journal.pone.0108094.t002

9.3860.41
301

0.04660.016

20.02360.017
9.3660.43

9.3960.41
813

735

20.04660.006

20.04560.005
0.9760.19

0.9660.18
360

760

0.03860.004
1.0060.17
Year 1, and change from baseline 814

Creatinine

Analyte

N

Analyte mg/dL

0.02160.004

Change in Analyte, mg/dL

4

N

813

1.0160.19

Analyte mg/dL

3
3

Change in Analyte mg/dL

4

Calcium Treatment Groups2
Control Treatment Groups1

Table 2. Blood Creatinine and Total Calcium Measurements for Participants in the Full Factorial Component of the Vitamin D/Calcium Polyp Prevention Study, by Calcium
Treatment Group.
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Table 3. Adjusted Effect Measures for the Association of Participant Characteristics with Year One Blood Creatinine Concentration
Using Multiple Linear Regression (N = 1,500).
Change3 (SE)

P

Baseline creatinine (per mg/dL)

0.747 (0.020)

,0.001

Age1 (per year)

0.0011 (0.0005)

0.01

Female sex

20.072 (0.010)

,0.001

Characteristics
1

Race:

0.85

Caucasian

reference

African American

0.001 (0.013)

Asian/Pacific Islander

20.016 (0.022)

Other/Unknown

20.010 (0.019)

Hispanic ethnicity

20.020 (0.022)

Smoking status:

0.36
0.01

Never

reference

Former

20.014 (0.006)

Current

20.031 (0.011)

Alcohol Intake (drinks/day)

0.02

0

reference

0.1–1.9

0.0004 (0.0071)

2–6

20.024 (0.010)

Dietary Calcium Intake1 (per 100 mg)

20.002 (0.001)

Diuretic Use2

0.015 (0.008)

0.05

Vitamin D Treatment Group

0.005 (0.006)

0.42

Calcium Treatment Group

0.013 (0.006)

0.03

0.02

Of N = 1,627 participants with year one creatinine available for analysis, 127 are not included due to missing data (see Table 1). CI, confidence interval.
Characteristics chosen for inclusion by backward elimination using the Akaike Information criterion for model selection, with race, Hispanic ethnicity and randomized
vitamin D treatment group forced into the model; characteristics are from baseline, except diuretic use (see 2); results for study centers not shown.
1
Characteristics are modeled as continuous variables with units as shown.
2
Diuretic use between baseline and year one blood draws.
3
Change in creatinine (mg/dL) associated with the exposure (mean, coefficient).
doi:10.1371/journal.pone.0108094.t003

(without vitamin D) is not very strong. Potential adverse effects
include kidney stones [16,45] and the emerging evidence on
cardiovascular risk [11,46]. Another consideration is whether
supplemental calcium has different effects than calcium that is
obtained from dietary sources and/or whether the effects may
differ according to the timing of intake relative to ingestion of food
[12,47–50]. Finally, calcium-based phosphate binders are routinely used to lower phosphorus levels in patients with chronic kidney
disease prior to end stage renal disease. While the effect of these
binders on kidney progression has not been evaluated systematically, in an observational study in Australia, phosphate binders
(type not specified) were associated with faster CDK progression
[51] and in a small randomized clinical trial comparing 3 different
clinically available phosphate binders, only a participant in the
calcium-based binder group experienced an episode of acute
kidney injury [52]. Based on our data and these other suggestive
analyses, studies are needed to evaluate the effects of calciumbased phosphate binders on kidney disease progression.
The strengths of this study include the well-characterized
population, with uniform and detailed collection of participant
characteristics at the time of enrollment. The randomized
exposure to calcium supplementation minimizes concerns about
confounding suggesting that the differences we observed could be
due to a causal effect. Participant compliance with study
procedures was excellent, including scheduled blood draws, pill
taking and avoidance of outside use of the study agents. Results are
PLOS ONE | www.plosone.org

generalizable to a putatively healthy outpatient population
receiving preventative health care, although the participants
analyzed were predominantly male, as 70% of women female
participants chose to receive calcium supplementation.
There are also several limitations. Blood creatinine concentration was used as a surrogate for renal function and we do not have
data on other markers of renal function nor did we directly
measure the glomerular filtration rate. In addition, creatinine
measurements were performed in many different laboratories and
some laboratories may have changed assays over the course of the
trial. Nonetheless, the additional variability introduced should not
differentially impact the randomized treatment groups and would
likely have biased our results towards the null. Also, given the small
effect size, we had limited power to detect effect modification in
the sub-group analyses. Finally, we did not measure blood ionized
calcium concentrations, and had to rely on total calcium.
In summary, results from a randomized placebo-controlled trial
indicate that supplementation with 1200 mg of elemental calcium
daily is associated with a small increase in blood creatinine in
healthy adults. This finding is important to investigate further,
considering that a large proportion of older individuals take
calcium supplements [2] and chronic kidney disease is a common
and growing public health threat in that population [53,54].

7

October 2014 | Volume 9 | Issue 10 | e108094

Calcium Supplementation and Creatinine Concentration

Supporting Information

Acknowledgments

Table S1 Blood Creatinine and Total Calcium Measurements Among Participants in the Full Factorial
Component of the Vitamin D/Calcium Polyp Prevention
Study with Blood Measurements Performed in the Same
Lab at the Prior Time Point, by Calcium Treatment
Group.
(DOCX)

The authors acknowledge the contributions of all of the Polyp Prevention
Study Group Investigators as well as the members of the Safety and Data
Monitoring Committee. We also appreciate the efforts of the Study
Coordinators, who were responsible for recruitment and follow-up of study
participants, and the Informatics and Coordination staff at the Dartmouth
Project Coordination Center. Finally, we are most grateful to all of the
study participants, whose long-term dedication and commitment made this
research possible.

Protocol S1 Trial Protocol.

Author Contributions

(DOC)
Checklist S1

Conceived and designed the experiments: JAB RMB RWS RSB DJA RSS
ELB. Performed the experiments: RSS DJA RSB RWS RMB. Analyzed
the data: LAM AI ELB. Wrote the paper: ELB LAM MLM JRR AI RSS
DJA RSB RWS RMB JAB.

CONSORT Checklist.

(DOC)

References
1. Dawson-Hughes B (2008) A Revised Clinician’s Guide to the Prevention and
Treatment of Osteoporosis. J Clin Endocrinol Metab 93: 2463–2465.
2. Bailey RL, Dodd KW, Goldman JA, Gahche JJ, Dwyer JT, et al. (2010)
Estimation of Total Usual Calcium and Vitamin D Intakes in the United States.
J Nutr 140: 817–822.
3. Mangano KM, Walsh SJ, Insogna KL, Kenny AM, Kerstetter JE (2011)
Calcium Intake in the United States from Dietary and Supplemental Sources
across Adult Age Groups: New Estimates from the National Health and
Nutrition Examination Survey 2003–2006. J Am Diet Assoc 111: 687–695.
4. Gahche J, Bailey R, Burt V, Hughes J, Yetley E, et al. (2011) Dietary
Supplement Use among U.S. Adults Has Increased since Nhanes Iii (1988–
1994). NCHS Data Brief: 1–8.
5. Baron JA, Beach M, Mandel JS, van Stolk RU, Haile RW, et al. (1999) Calcium
Supplements for the Prevention of Colorectal Adenomas. Calcium Polyp
Prevention Study Group. N Engl J Med 340: 101–107.
6. Cho E, Smith-Warner SA, Spiegelman D, Beeson WL, van den Brandt PA, et al.
(2004) Dairy Foods, Calcium, and Colorectal Cancer: A Pooled Analysis of 10
Cohort Studies. J Natl Cancer Inst 96: 1015–1022.
7. Shaukat A, Scouras N, Schunemann HJ (2005) Role of Supplemental Calcium
in the Recurrence of Colorectal Adenomas: A Metaanalysis of Randomized
Controlled Trials. Am J Gastroenterol 100: 390–394.
8. Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, et al. (2011) The
2011 Report on Dietary Reference Intakes for Calcium and Vitamin D from the
Institute of Medicine: What Clinicians Need to Know. J Clin Endocrinol Metab
96: 53–58.
9. Bolland MJ, Barber PA, Doughty RN, Mason B, Horne A, et al. (2008) Vascular
Events in Healthy Older Women Receiving Calcium Supplementation:
Randomised Controlled Trial. BMJ 336: 262–266.
10. Bolland MJ, Avenell A, Baron JA, Grey A, MacLennan GS, et al. (2010) Effect
of Calcium Supplements on Risk of Myocardial Infarction and Cardiovascular
Events: Meta-Analysis. BMJ 341: c3691.
11. Bolland MJ, Grey A, Avenell A, Gamble GD, Reid IR (2011) Calcium
Supplements with or without Vitamin D and Risk of Cardiovascular Events:
Reanalysis of the Women’s Health Initiative Limited Access Dataset and MetaAnalysis. BMJ 342: d2040.
12. Xiao Q, Murphy RA, Houston DK, Harris TB, Chow WH, et al. (2013) Dietary
and Supplemental Calcium Intake and Cardiovascular Disease Mortality: The
National Institutes of Health-Aarp Diet and Health Study. JAMA Intern Med
173: 639–646.
13. Lewis JR, Calver J, Zhu K, Flicker L, Prince RL (2011) Calcium
Supplementation and the Risks of Atherosclerotic Vascular Disease in Older
Women: Results of a 5-Year Rct and a 4.5-Year Follow-Up. J Bone Miner Res
26: 35–41.
14. Mursu J, Robien K, Harnack LJ, Park K, Jacobs DR, Jr. (2011) Dietary
Supplements and Mortality Rate in Older Women: The Iowa Women’s Health
Study. Arch Intern Med 171: 1625–1633.
15. Rejnmark L, Avenell A, Masud T, Anderson F, Meyer HE, et al. (2012) Vitamin
D with Calcium Reduces Mortality: Patient Level Pooled Analysis of 70,528
Patients from Eight Major Vitamin D Trials. J Clin Endocrinol Metab 97:
2670–2681.
16. Wallace RB, Wactawski-Wende J, O’Sullivan MJ, Larson JC, Cochrane B, et al.
(2011) Urinary Tract Stone Occurrence in the Women’s Health Initiative (Whi)
Randomized Clinical Trial of Calcium and Vitamin D Supplements. Am J Clin
Nutr 94: 270–277.
17. Patel AM, Adeseun GA, Goldfarb S (2013) Calcium-Alkali Syndrome in the
Modern Era. Nutrients 5: 4880–4893.
18. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, et al. (2009) A
New Equation to Estimate Glomerular Filtration Rate. Ann Intern Med 150:
604–612.
19. Smith EL, Gilligan C, Smith PE, Sempos CT (1989) Calcium Supplementation
and Bone Loss in Middle-Aged Women. Am J Clin Nutr 50: 833–842.

PLOS ONE | www.plosone.org

20. Dawson-Hughes B, Dallal GE, Krall EA, Sadowski L, Sahyoun N, et al. (1990)
A Controlled Trial of the Effect of Calcium Supplementation on Bone Density in
Postmenopausal Women. N Engl J Med 323: 878–883.
21. Reid IR, Ames RW, Evans MC, Gamble GD, Sharpe SJ (1993) Effect of
Calcium Supplementation on Bone Loss in Postmenopausal Women.
N Engl J Med 328: 460–464.
22. Recker RR, Hinders S, Davies KM, Heaney RP, Stegman MR, et al. (1996)
Correcting Calcium Nutritional Deficiency Prevents Spine Fractures in Elderly
Women. J Bone Miner Res 11: 1961–1966.
23. Riggs BL, O’Fallon WM, Muhs J, O’Connor MK, Kumar R, et al. (1998) LongTerm Effects of Calcium Supplementation on Serum Parathyroid Hormone
Level, Bone Turnover, and Bone Loss in Elderly Women. J Bone Miner Res 13:
168–174.
24. Grant AM, Avenell A, Campbell MK, McDonald AM, MacLennan GS, et al.
(2005) Oral Vitamin D3 and Calcium for Secondary Prevention of Low-Trauma
Fractures in Elderly People (Randomised Evaluation of Calcium or Vitamin D,
Record): A Randomised Placebo-Controlled Trial. Lancet 365: 1621–1628.
25. Prince RL, Devine A, Dhaliwal SS, Dick IM (2006) Effects of Calcium
Supplementation on Clinical Fracture and Bone Structure: Results of a 5-Year,
Double-Blind, Placebo-Controlled Trial in Elderly Women. Arch Intern Med
166: 869–875.
26. Reid IR, Mason B, Horne A, Ames R, Reid HE, et al. (2006) Randomized
Controlled Trial of Calcium in Healthy Older Women. Am J Med 119: 777–
785.
27. Bonnick S, Broy S, Kaiser F, Teutsch C, Rosenberg E, et al. (2007) Treatment
with Alendronate Plus Calcium, Alendronate Alone, or Calcium Alone for
Postmenopausal Low Bone Mineral Density. Curr Med Res Opin 23: 1341–
1349.
28. Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP (2007)
Vitamin D and Calcium Supplementation Reduces Cancer Risk: Results of a
Randomized Trial. Am J Clin Nutr 85: 1586–1591.
29. Reid IR, Bolland MJ, Grey A (2008) Effect of Calcium Supplementation on Hip
Fractures. Osteoporos Int 19: 1119–1123.
30. Hofstad B, Vatn MH, Andersen SN, Owen RW, Larsen S, et al. (1998) The
Relationship between Faecal Bile Acid Profile with or without Supplementation
with Calcium and Antioxidants on Recurrence and Growth of Colorectal
Polyps. Eur J Cancer Prev 7: 287–294.
31. Bonithon-Kopp C, Kronborg O, Giacosa A, Rath U, Faivre J (2000) Calcium
and Fibre Supplementation in Prevention of Colorectal Adenoma Recurrence:
A Randomised Intervention Trial. European Cancer Prevention Organisation
Study Group. Lancet 356: 1300–1306.
32. Wactawski-Wende J, Kotchen JM, Anderson GL, Assaf AR, Brunner RL, et al.
(2006) Calcium Plus Vitamin D Supplementation and the Risk of Colorectal
Cancer. N Engl J Med 354: 684–696.
33. Peacock M, Liu G, Carey M, McClintock R, Ambrosius W, et al. (2000) Effect of
Calcium or 25oh Vitamin D3 Dietary Supplementation on Bone Loss at the Hip
in Men and Women over the Age of 60. J Clin Endocrinol Metab 85: 3011–
3019.
34. Elders PJ, Netelenbos JC, Lips P, van Ginkel FC, Khoe E, et al. (1991) Calcium
Supplementation Reduces Vertebral Bone Loss in Perimenopausal Women: A
Controlled Trial in 248 Women between 46 and 55 Years of Age. J Clin
Endocrinol Metab 73: 533–540.
35. Dazai Y, Iwata T, Hiwada K (1993) Augmentation of the Renal Tubular
Dopaminergic Activity by Oral Calcium Supplementation in Patients with
Essential Hypertension. Am J Hypertens 6: 933–937.
36. Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ (2000) Plasma Lipids and
Risk of Developing Renal Dysfunction: The Atherosclerosis Risk in Communities Study. Kidney International 58: 293–301.
37. Agarwal R, Hynson JE, Hecht TJ, Light RP, Sinha AD (2011) Short-Term
Vitamin D Receptor Activation Increases Serum Creatinine Due to Increased

8

October 2014 | Volume 9 | Issue 10 | e108094

Calcium Supplementation and Creatinine Concentration

38.

39.

40.

41.
42.

43.
44.

45.

46. Prentice RL, Pettinger MB, Jackson RD, Wactawski-Wende J, Lacroix AZ, et al.
(2013) Health Risks and Benefits from Calcium and Vitamin D Supplementation: Women’s Health Initiative Clinical Trial and Cohort Study. Osteoporos Int
24: 567–580.
47. Green JH, Booth C, Bunning R (2003) Postprandial Metabolic Responses to
Milk Enriched with Milk Calcium Are Different from Responses to Milk
Enriched with Calcium Carbonate. Asia Pac J Clin Nutr 12: 109–119.
48. Curhan GC, Willett WC, Knight EL, Stampfer MJ (2004) Dietary Factors and
the Risk of Incident Kidney Stones in Younger Women: Nurses’ Health Study Ii.
Arch Intern Med 164: 885–891.
49. Favus MJ (2011) The Risk of Kidney Stone Formation: The Form of Calcium
Matters. Am J Clin Nutr 94: 5–6.
50. Li K, Kaaks R, Linseisen J, Rohrmann S (2012) Associations of Dietary Calcium
Intake and Calcium Supplementation with Myocardial Infarction and Stroke
Risk and Overall Cardiovascular Mortality in the Heidelberg Cohort of the
European Prospective Investigation into Cancer and Nutrition Study (EpicHeidelberg). Heart 98: 920–925.
51. Boudville N, Kemp A, Moody H, Fassett RG, Pedagogos E, et al. (2012) Factors
Associated with Chronic Kidney Disease Progression in Australian Nephrology
Practices. Nephron Clin Pract 121: c36–41.
52. Block GA, Wheeler DC, Persky MS, Kestenbaum B, Ketteler M, et al. (2012)
Effects of Phosphate Binders in Moderate Ckd. J Am Soc Nephrol 23: 1407–
1415.
53. James MT, Hemmelgarn BR, Tonelli M (2010) Early Recognition and
Prevention of Chronic Kidney Disease. Lancet 375: 1296–1309.
54. Levey AS, Coresh J (2012) Chronic Kidney Disease. Lancet 379: 165–180.

Production with No Effect on the Glomerular Filtration Rate. Kidney
international 80: 1073–1079.
Shlipak MG, Katz R, Kestenbaum B, Siscovick D, Fried L, et al. (2009) Rapid
Decline of Kidney Function Increases Cardiovascular Risk in the Elderly. J Am
Soc Nephrol 20: 2625–2630.
Rifkin DE, Shlipak MG, Katz R, Fried LF, Siscovick D, et al. (2008) Rapid
Kidney Function Decline and Mortality Risk in Older Adults. Arch Intern Med
168: 2212–2218.
Holtkamp FA, de Zeeuw D, Thomas MC, Cooper ME, de Graeff PA, et al.
(2011) An Acute Fall in Estimated Glomerular Filtration Rate During Treatment
with Losartan Predicts a Slower Decrease in Long-Term Renal Function.
Kidney International 80: 282–287.
Woo JJ (2007) Adverse Event Monitoring and Multivitamin-Multimineral
Dietary Supplements. Am J Clin Nutr 85: 323S–324S.
Mulholland CA, Benford DJ (2007) What Is Known About the Safety of
Multivitamin-Multimineral Supplements for the Generally Healthy Population?
Theoretical Basis for Harm. Am J Clin Nutr 85: 318S–322S.
Ross AC, Taylor CL, Yaktine AL, Del Valle HB (2011) Dietary Reference
Intakes for Calcium and Vitamin D. Washington DC: National Academies.
Moyer VA, U.S. Preventive Services Task Force (2013) Vitamin D and Calcium
Supplementation to Prevent Fractures in Adults: U.S. Preventive Services Task
Force Recommendation Statement. Ann Intern Med 158: 691–696.
Jackson RD, LaCroix AZ, Gass M, Wallace RB, Robbins J, et al. (2006)
Calcium Plus Vitamin D Supplementation and the Risk of Fractures.
N Engl J Med 354: 669–683.

PLOS ONE | www.plosone.org

9

October 2014 | Volume 9 | Issue 10 | e108094

